Article ISI SCOPUS
Clinical Lung Cancer  (2020)

Complete Response to Immunotherapy Plus Chemotherapy After an Unusual Clinical Response to Afatinib and Stereotactic Radiosurgery in a Patient With Metastatic EGFR-Mutant Non-Small-Cell Lung Cancer

Pizarro G.; Pinto, M. P.; Muñoz-Medel M.; Cordova-Delgado M.; Bravo, M. L.; Nervi B.; Sánchez C.; Ibañez C.; Peña J.; Walbaum B.; Madrid J.; Briones J.; Koch E.; Valbuena J.; Gonzalez S.; et. al.

Abstract

Tyrosine kinase inhibitors are the standard of care for epidermal growth factor (EGFR)-mutant non-small-cell lung cancer (NSCLC) patients. Studies suggest no significant benefit of immune checkpoint inhibitors (CPI) for these patients.

Más información

Título según WOS: Complete Response to Immunotherapy Plus Chemotherapy After an Unusual Clinical Response to Afatinib and Stereotactic Radiosurgery in a Patient With Metastatic EGFR-Mutant Non-Small-Cell Lung Cancer
Título según SCOPUS: Complete Response to Immunotherapy Plus Chemotherapy After an Unusual Clinical Response to Afatinib and Stereotactic Radiosurgery in a Patient With Metastatic EGFR-Mutant Non–Small-Cell Lung Cancer
Título de la Revista: Clinical Lung Cancer
Volumen: 21
Número: 4
Fecha de publicación: 2020
Idioma: English
DOI:

10.1016/J.CLLC.2020.01.012
Notas: ISI, SCOPUS